Back HIV Treatment

HIV Treatment

ICAAC 2008: Experimental NRTI Elvucitabine Suppresses HIV as well as Lamivudine at 48 Weeks

While novel classes of antiretroviral drugs such as integrase inhibitors and CCR5 antagonists have received the most attention at recent HIV conferences, new agents in older classes also continue to make their way through the pipeline. At the 48th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2008) last week in Washington, DC, researchers presented the latest data on elvucitabine (also known as ACH123,446), a cytosine analog nucleoside reverse transcriptase inhibitor (NRTI) being developed by Achillion Pharmaceuticals. Previous laboratory studies demonstrated potent in vitro activity against wild type HIV-1.

Read more:

ICAAC 2008: Abacavir/lamivudine plus Boosted Atazanavir Provides Potent Antiviral Activity at All Viral Load Levels

Recently presented data have offered conflicting evidence concerning the relative effectiveness of nucleoside reverse transcriptase inhibitor (NRTI) backbone combinations using abacavir or tenofovir. New data presented this week at the 48th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2008) in Washington, DC, provide further support for both sides of the debate. (The HEAT and GlaxoSmithKline trial review results were presented again as posters at ICAAC.)

Read more:

ICAAC 2008: Long-term Safety of Investigational CCR5 Antagonist Vicriviroc in Treatment-experienced Patients

Schering-Plough's investigational CCR5 antagonist vicriviroc has demonstrated potent activity against HIV in laboratory studies and clinical trials of treatment-experienced patients. More than 200 patients received vicriviroc in Phase II trials. In a poster presented at the 48th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2008), taking place this week in Washington, DC, researchers described long-term safety data from this population.

Read more:

ICAAC 2008: Boosted Atazanavir (Reyataz) and Lopinavir/ritonavir (Kaletra) Are both Highly Effective through 96 Weeks

Long-term clinical trial data show that modern HAART regimens offer continued antiviral efficacy over time, although toxicities remain a concern.

Read more:

ICAAC 2008: Efficacy and Safety of Boosted Darunavir (Prezista) Are Comparable to Lopinavir/ritonavir (Kaletra) at 96 Weeks: ARTEMIS Trial

Tibotec's second-generation protease inhibitor darunavir (Prezista) was approved in June 2006 for treatment-experienced HIV patients, to be administered at 600 mg boosted with 100 mg ritonavir twice-daily. As previously reported, in the Phase III ARTEMIS trial darunavir/ritonavir demonstrated safety and efficacy comparable to that of lopinavir/ritonavir (Kaletra) at 48 weeks. In a late-breaker session at the 48th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2008), taking place this week in Washington, DC, researchers presented longer-term 96-week data from the study. Follow-up is scheduled to continue through 192 weeks.Boosted darunavir has also been studied in treatment-naive individuals, and earlier this month received approval for use in this patient population.

Read more: